Michael Bhatt

Michael Bhatt has advanced the clinical combination of TGF-beta inhibitors with immune checkpoint blockade, demonstrating that TGF-beta is a master regulator of T cell exclusion from the tumor microenvironment and that its neutralization converts immune-excluded cold tumors into inflamed hot tumors responsive to checkpoint immunotherapy. His research showed that TGF-beta promotes regulatory T cell differentiation while suppressing cytotoxic CD8+ T cell effector function in the tumor microenvironment. He conducted clinical trials showing that TGF-beta inhibition increases tumor T cell infiltration and enhances PD-1 blockade efficacy in urothelial carcinoma. His translational work is defining optimal patient selection for TGF-beta plus immunotherapy combinations.